Antoine Elias
Antoine Elias has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Laurent Bertoletti
Université Jean Monnet Saint-Étienne, CHU Saint-Étienne, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, CIC 1408, Département of Médecine Vasculaire et Thérapeutique, F-CRIN INNOVTE network, Saint-Etienne, France
9 shared publications - Olivier Sanchez
Paris Cité University, Paris, France
9 shared publications - Isabelle Mahé
Assistance Publique - Hopitaux de Paris, Île-de-France, France
8 shared publications - Philippe Girard
F-CRIN INNOVTE network, Saint-Étienne, France; Institut du thorax Curie-Montsouris, Institut mutualiste Montsouris, Paris, France
8 shared publications - Francis Couturaud
INSERM UMR 1304‐GETBO, Univ Brest Brest France
7 shared publications - Jeannot Schmidt
Emergency Department, CHU Clermont-Ferrand, Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, F-63000 Clermont-Ferrand, France
7 shared publications
Latest Publications
- Open Access
Direct Oral Factor-Xa Inhibitors in Patients with Acute Venous Thromboembolism and Renal Impairment. A randomized controlled trial
BACKGROUND: In patients with venous thromboembolism (VTE), renal impairment increases the risks for both recurrence and bleeding. Because these patients are underrepresented in clinical trials, we assessed whether standard direct factor Xa inhibitor (DXI) lead-in followed by early dose reduction was noninferior to standard anticoagulation in patients with acute VTE and moderate-to-severe renal impairment. METHODS: The VERDICT trial was a randomized, prospective, multicenter, open-label, blinded-endpoint, noninferiority trial. Consecutive patients with acute proximal deep-vein thrombosis or pulmonary embolism and chronic renal impairment (creatinine clearance 15–50 mL/min) were randomized 1:1 to an early DXI dose reduction strategy or standard therapy (heparin plus a vitamin K antagonist). Patients allocated to the DXI strategy underwent a second 1:1 randomization to apixaban or rivaroxaban, each administered at an initial standard lead-in dose followed by early dose reduction. The primary outcome was net clinical benefit at 3 months, defined as the composite of major bleeding and symptomatic recurrent VTE. RESULTS: Due to slow recruitment, the trial was prematurely terminated after enrolling 200 of the planned 800 patients (DXI: n=104; standard: n=96). The median age was 85.9 years, 31% were male, and 29.0% had severe renal impairment. The primary outcome occurred in 8 patients (7.7%) in the DXI group and 9 patients (9.3%) in the standard therapy group (adjusted subhazard ratio [sHR], 0.87; 95% CI, 0.26 to 2.87; P = 0.19 for noninferiority; noninferiority margin 1.30). Major bleeding occurred in 6.7% and 6.2% of patients and recurrent VTE occurred in 1.0% and 3.1% of patients, respectively. CONCLUSION: In patients with VTE and moderate-to-severe renal impairment, noninferiority of an early DXI dose-reduction strategy versus standard therapy could not be demonstrated for net clinical benefit. Although no major differences in efficacy or safety outcomes were observed between groups, the reduced sample size precludes definitive conclusions. Clinical Trial Registration: URL: https://clinicaltrials.gov . Unique identifier: NCT02664155 Clinical Perspective: What Is New?: The VERDICT trial is the first randomized controlled trial specifically designed to assess an initial frontloaded standard dose of oral direct factor Xa inhibitor followed by early dose reduction strategy versus standard anticoagulation therapy for acute venous thromboembolism in patients with moderate-to-severe renal impairment. Reflecting real-world clinical practice, the study successfully enrolled an exceptionally elderly and frail population with a median age of 85.9 years. A meta-analysis incorporating VERDICT and renal impairment subgroups from previous VTE trials showed a 35% relative reduction in net clinical benefit and a 53% relative reduction in major bleeding with DXI versus standard therapy with heparins/VKA. What Are the Clinical Implications?: Although premature trial termination limited statistical power to formally demonstrate noninferiority, the findings did not differ from those observed in renal impairment subgroups of previous randomized VTE trials. The available evidence provides a rationale for evaluating an early dose-reduction strategy in frail patients with VTE.
Open AccessDirect Oral Factor-Xa Inhibitors in Patients with Acute Venous Thromboembolism and Renal Impairment. A randomized controlled trial
BACKGROUND: In patients with venous thromboembolism (VTE), renal impairment increases the risks for both recurrence and bleeding. Because these patients are underrepresented in clinical trials, we assessed whether standard direct factor Xa inhibitor (DXI) lead-in followed by early dose reduction was noninferior to standard anticoagulation in patients with acute VTE and moderate-to-severe renal impairment. METHODS: The VERDICT trial was a randomized, prospective, multicenter, open-label, blinded-endpoint, noninferiority trial. Consecutive patients with acute proximal deep-vein thrombosis or pulmonary embolism and chronic renal impairment (creatinine clearance 15–50 mL/min) were randomized 1:1 to an early DXI dose reduction strategy or standard therapy (heparin plus a vitamin K antagonist). Patients allocated to the DXI strategy underwent a second 1:1 randomization to apixaban or rivaroxaban, each administered at an initial standard lead-in dose followed by early dose reduction. The primary outcome was net clinical benefit at 3 months, defined as the composite of major bleeding and symptomatic recurrent VTE. RESULTS: Due to slow recruitment, the trial was prematurely terminated after enrolling 200 of the planned 800 patients (DXI: n=104; standard: n=96). The median age was 85.9 years, 31% were male, and 29.0% had severe renal impairment. The primary outcome occurred in 8 patients (7.7%) in the DXI group and 9 patients (9.3%) in the standard therapy group (adjusted subhazard ratio [sHR], 0.87; 95% CI, 0.26 to 2.87; P = 0.19 for noninferiority; noninferiority margin 1.30). Major bleeding occurred in 6.7% and 6.2% of patients and recurrent VTE occurred in 1.0% and 3.1% of patients, respectively. CONCLUSION: In patients with VTE and moderate-to-severe renal impairment, noninferiority of an early DXI dose-reduction strategy versus standard therapy could not be demonstrated for net clinical benefit. Although no major differences in efficacy or safety outcomes were observed between groups, the reduced sample size precludes definitive conclusions. Clinical Trial Registration: URL: https://clinicaltrials.gov . Unique identifier: NCT02664155 Clinical Perspective: What Is New?: The VERDICT trial is the first randomized controlled trial specifically designed to assess an initial frontloaded standard dose of oral direct factor Xa inhibitor followed by early dose reduction strategy versus standard anticoagulation therapy for acute venous thromboembolism in patients with moderate-to-severe renal impairment. Reflecting real-world clinical practice, the study successfully enrolled an exceptionally elderly and frail population with a median age of 85.9 years. A meta-analysis incorporating VERDICT and renal impairment subgroups from previous VTE trials showed a 35% relative reduction in net clinical benefit and a 53% relative reduction in major bleeding with DXI versus standard therapy with heparins/VKA. What Are the Clinical Implications?: Although premature trial termination limited statistical power to formally demonstrate noninferiority, the findings did not differ from those observed in renal impairment subgroups of previous randomized VTE trials. The available evidence provides a rationale for evaluating an early dose-reduction strategy in frail patients with VTE.
- Open Access
- 3 February 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 72 (4) , 689-697
A French Practice Survey of Diagnostic Assessment and Compression Therapy for Patients with Venous Leg Ulcers and Peripheral Artery Disease
- 3 February 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 72 (4) , 689-697
Open AccessA French Practice Survey of Diagnostic Assessment and Compression Therapy for Patients with Venous Leg Ulcers and Peripheral Artery Disease
- Open Access
- 28 August 2025
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 118 (12) , 687-696
The management of cancer-associated thromboembolism: Proposals from the French multidisciplinary INNOVTE CAT Working Group
- 28 August 2025
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 118 (12) , 687-696
Open AccessThe management of cancer-associated thromboembolism: Proposals from the French multidisciplinary INNOVTE CAT Working Group
- 10 September 2024
- Published by Elsevier in JMV-Journal de Médecine Vasculaire
- Vol. 49 (3-4) , 176-185
Update on the diagnosis of recurrence of lower limb deep vein thrombosis. A Consensus statement of the French Society for Vascular Medicine (SFMV)
- 10 September 2024
- Published by Elsevier in JMV-Journal de Médecine Vasculaire
- Vol. 49 (3-4) , 176-185
Update on the diagnosis of recurrence of lower limb deep vein thrombosis. A Consensus statement of the French Society for Vascular Medicine (SFMV)
- 3 August 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (8) , 498-511
Traduction et republication de : « Événements thromboemboliques artériels liés au cancer »
- 3 August 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (8) , 498-511
Traduction et republication de : « Événements thromboemboliques artériels liés au cancer »
- 21 June 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (7) , 437-443
Traduction et republication de : « Traitement de la maladie thromboembolique veineuse associée au cancer chez les patients en soins palliatifs »
- 21 June 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (7) , 437-443
Traduction et republication de : « Traitement de la maladie thromboembolique veineuse associée au cancer chez les patients en soins palliatifs »
- 27 May 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (5) , 289-299
Traduction et republication de : « Maladie thromboembolique veineuse récidivante chez les patients cancéreux anticoagulés : diagnostic et traitement »
- 27 May 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (5) , 289-299
Traduction et republication de : « Maladie thromboembolique veineuse récidivante chez les patients cancéreux anticoagulés : diagnostic et traitement »
- 23 May 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (6) , 366-381
Traduction et republication de : « Prise en charge de la maladie thromboembolique veineuse associée au cancer chez les populations vulnérables »
- 23 May 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (6) , 366-381
Traduction et republication de : « Prise en charge de la maladie thromboembolique veineuse associée au cancer chez les populations vulnérables »
- Open Access
- 15 March 2024
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 296, 342-348
Evaluation of Elastic Venous Compression Device dispensation in pregnant and post-partum women using the French National Health Insurance Claims Database: The ProFIL retrospective cohort study
- 15 March 2024
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 296, 342-348
Open AccessEvaluation of Elastic Venous Compression Device dispensation in pregnant and post-partum women using the French National Health Insurance Claims Database: The ProFIL retrospective cohort study